XBiotech Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Registration Statement Declared Effective as of Today
Tweet
Share
E-mailAUSTIN, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- XBiotech Inc., a leading developer of next-generation therapeutic antibodies, announced today the pricing of its initial public offering of 4,000,000 shares of its common stock at an initial public offering price of $19.00 per share for a total offering amount of $76,000,000, before the underwriting discount. The shares are expected to begin trading on the Nasdaq Global Select Market on Wednesday, April 15, 2015 under the ticker symbol "XBIT."
WR Hambrecht + Co is acting as the sole underwriter for the offering.
This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering is being made only by means of a written prospectus. Copies of the final prospectus relating to the offering may be obtained from WR Hambrecht + Co at www.wrhambrecht.com, by calling 1-800-673-6476, or by writing to 909 Montgomery Street, 3rd Floor, San Francisco, CA 94133.
About XBiotech
XBiotech is a leading developer of next-generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.
CONTACT: Ashley Otero
XBiotech
[email protected]
(512) 386-2930
Tiberend Strategic Advisors:
Joshua Drumm, Ph.D.
[email protected]
(212) 375-2664
Jason Rando (media)
[email protected]
(212) 375-2665
Source: XBiotech
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arista Networks shares jump on upbeat Q3 results, strong guidance
- Automotive Financing Market Size to Reach USD 505.59 Billion by 2031, Driven by Growing Vehicle Demand and Digital Lending Solutions – Mordor Intelligence
- E.SUN Debuts at COP17, Showcasing Taiwan’s Nature Finance in Action
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
WR Hambrecht + Co., IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
